caret icon Back to all discussions

progression: positive and negative results

Since August 17, 2021, I am on clinical trial with Tecentriq (immunothrapy) and Cabozantinib.

Since April, I have experienced some progression.

Mix results with immunotherapy:
I have a metastasis which appeared and other metastasis still shrinking.
In August, I have a metastasis that was growing instead of shrinking.
Went twice to SBRT to destroy the tumors.
It looks like tecentriq is unable to control the cancer.

What will you do in my case?
Live the clinical tria?
or
stay and try to see what will happen next?

  1. I am sorry to hear of your progression. Did your doctor try to get another tissue or needle biopsy or a liquid biopsy after progression to see if you have developed any new mutations? I think that should be the next step if not already done. I am also a big believer in second opinions in a separate Comprehensive Cancer Center, have you ever sought one? Thinking of you and wishing you the very best, Alisa, LungCancer.net Patient Leader


    1. Thanks for taking the time to respond.


      Next time a biopsy will be done according to the investigator of the clinical trial. Right now we are obtaining mix results from immunotherapy agent (tecentriq).


      Next week, I will get an infusion and the following week a ct scan.


      It look like no one want to interfere with the clinical trial because of complicated situation (mix results).

      1. Wishing you the very best with your upcoming treatment and follow up scan. I'll be thinking of you, please feel free to update us. ~ Alisa

    2. Sorry to hear about your progression as well. I agree with Alisa, as a second eye is not a bad thing; considering you mentioned the complexity due to the clinical trial... I can only imagine how frustrated and uncertain how to move this along. I hope everything goes well in the next few weeks, and hopefully it can stir the team in how to further move forward with your treatment. Wishing you the very best!

      or create an account to reply.